The use of neuromuscular blocking agents (NMBAs) in patients with acute respiratory distress syndrome (ARDS) is associated with a host of negative effects, including increased in-hospital mortality and prolonged duration of mechanical ventilation and hospital length of stay, a new study has found.
These data, the researchers said, confirm the safety concerns raised in the ROSE trial, published last year in The New England Journal of Medicine (2019;380:1997-2008).
“There are two studies with